Should You Buy Ingredion Inc (INGR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
117.200
1 Day change
0.64%
52 Week Range
141.780
Analysis Updated At
2026/01/29
Ingredion Inc (INGR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While hedge funds are increasing their positions, the company's financial performance has weakened, analysts have downgraded the stock, and there are no significant positive catalysts to offset the risks. The technical indicators suggest a neutral trend, and options data shows bearish sentiment. Given the investor's background and preference for long-term investments, holding off on buying this stock until there is more clarity on its financial recovery and demand trends is advisable.
Technical Analysis
The MACD is positive at 0.198, indicating slight bullish momentum, but it is contracting. RSI is at 70.478, suggesting a neutral zone with no strong signal. Moving averages are converging, indicating indecision. The stock is trading near its resistance level of 117.875, with support at 113.971. Overall, the technical indicators suggest a neutral trend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
The high put-call volume ratio of 2.0 indicates bearish sentiment, and the implied volatility percentile of 84.4 suggests elevated uncertainty in the market.
Technical Summary
Sell
4
Buy
8
Positive Catalysts
Hedge funds are increasing their positions, with a 137.50% rise in buying activity over the last quarter. The company's alignment with health food trends could be a long-term positive factor.
Neutral/Negative Catalysts
Analysts have downgraded the stock, citing weak demand in the Food and Industrial Ingredients segment, operational challenges, and economic issues in Latin America. The company's Q3 financials show declining revenue, net income, and EPS. Additionally, the retirement of the CFO adds uncertainty.
Financial Performance
In Q3 2025, Ingredion's revenue dropped by -2.89% YoY to $1.816 billion. Net income decreased by -9.04% YoY to $171 million, and EPS declined by -7.77% YoY to 2.61. Gross margin also fell to 25.06%, down -2.15% YoY. These metrics indicate a weakening financial performance.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Barclays downgraded the stock to Equal Weight from Overweight, with a reduced price target of $124 (down from $168). UBS and BMO Capital also lowered their price targets to $119 and $123, respectively, citing weak demand, operational challenges, and economic headwinds in Latin America. Analysts maintain a cautious outlook on the stock.
Wall Street analysts forecast INGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INGR is 125.5 USD with a low forecast of 119 USD and a high forecast of 136 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast INGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INGR is 125.5 USD with a low forecast of 119 USD and a high forecast of 136 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 116.450
Low
119
Averages
125.5
High
136
Current: 116.450
Low
119
Averages
125.5
High
136
Barclays
Overweight -> Equal Weight
downgrade
$168 -> $124
AI Analysis
2025-11-06
Reason
Barclays
Price Target
$168 -> $124
AI Analysis
2025-11-06
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Ingredion to Equal Weight from Overweight with a price target of $124, down from $168. The firm says that while the company's primary Texture and Healthful Solutions segment continues to post solid volume and profit growth, it has increased caution around its Food and Industrial Ingredients unit in both Latin America and the U.S. Continued demand weakness in the segment will be an overhang on Ingredion's profit growth, the analyst tells investors in a research note. Barclays also believes that lower economic activity in Brazil and Mexico will continue to negatively impact both the company's volumes and profits for the medium term.
BMO Capital
Andrew Strelzik
Market Perform
downgrade
$143 -> $123
2025-11-05
Reason
BMO Capital
Andrew Strelzik
Price Target
$143 -> $123
2025-11-05
downgrade
Market Perform
Reason
BMO Capital analyst Andrew Strelzik lowered the firm's price target on Ingredion to $123 from $143 and keeps a Market Perform rating on the shares. Volume declines accelerated in both FII segments attributed to softer demand, Argo operations issues, and disruption with a LATAM customer, the analyst tells investors in a research note. The stock trades at an attractive valuation, but a multiple discount is warranted for ongoing demand and pricing power risks, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INGR
